Disease · MONDO_0006486
uveal melanoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. uveal melanoma. Diseases, record MONDO_0006486. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006486
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- choroidal melanoma, intraocular melanoma, iris melanoma, melanoma (disease) of uvea, melanoma of the uvea, melanoma of uvea, melanoma, uveal, malignant, uvea melanoma, uvea melanoma (disease)
- Open Targets
- Highest stage of its drugs
- Phase 3, for 9 of its 84 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs84
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 3 | ClinicalTrials.gov | 19 | 19 | 19 | Drugs and targets |
| IPILIMUMAB | CHEMBL1789844 | Antibody | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| DAROVASERTIB | CHEMBL3982723 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| MELPHALAN | CHEMBL852 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| DACARBAZINE | CHEMBL476 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| SELUMETINIB | CHEMBL1614701 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BELZUPACAP SAROTALOCAN | CHEMBL4802193 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FOTEMUSTINE | CHEMBL549386 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MELPHALAN HYDROCHLORIDE | CHEMBL1200863 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| CRIZOTINIB | CHEMBL601719 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 84
See all 84 drugsTargets131
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 131
See all 131 targetsTrials97
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03070392 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | Phase 2 | 378 | 2021-09-14 | Uveal Melanoma | DACARBAZINE, IPILIMUMAB, PEMBROLIZUMAB, TEBENTAFUSP | Its record names the disease | ClinicalTrials.gov |
| NCT03733990 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Phase 1/2 | 216 | 2025-04-02 | Cancer | BEXMARILIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01974752 | Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) | Phase 3 | 152 | 2016-09-28 | Metastatic, Uveal Melanoma | DACARBAZINE, SELUMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02570308 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | Phase 1/2 | 146 | 2021-09-01 | Uveal Melanoma | TEBENTAFUSP | Its record names the disease | ClinicalTrials.gov |
| NCT01143402 | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | Phase 2 | 120 | 2017-05-18 | Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IV Uveal Melanoma | SELUMETINIB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01585194 | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | Phase 2 | 67 | 2020-12-10 | Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00506142 | Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma | Phase 2 | 54 | 2019-11-27 | Metastatic Malignant Uveal Melanoma | VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT00661622 | Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF | Phase 2 | 53 | 2015-06-01 | Uveal Melanoma, Liver Metastases | REGRAMOSTIM | Its record names the disease | ClinicalTrials.gov |
| NCT01979523 | Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | Phase 2 | 42 | 2020-02-24 | Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 | TRAMETINIB, UPROSERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT01100528 | Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance | Phase 2 | 38 | 2018-10-29 | Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Recurrent Intraocular Melanoma | DACARBAZINE, INTERFERON ALFA-2B | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 97
See all 97 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tebentafusp vs Investigator's Choice: Safety: Number of Participants With Treatment Emergent Adverse Events | 245 of 245 | 105 of 111 | 356 | NCT03070392 | Trial comparisons |
| Tebentafusp vs Investigator's Choice: deaths from any cause | 84 of 245 | 57 of 111 | 356 | NCT03070392 | Trial comparisons |
| Tebentafusp vs Investigator's Choice: serious adverse events | 69 of 245 | 26 of 111 | 356 | NCT03070392 | Trial comparisons |
| Placebo + Dacarbazine 1000 mg/m2 vs Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2: serious adverse events | 2 of 32 | 20 of 97 | 129 | NCT01974752 | Trial comparisons |
| Cohort 1 vs Cohort 2: Disease Control Rate | 18 of 35 | 8 of 19 | 54 | NCT00506142 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 15 of 35 | 9 of 19 | 54 | NCT00506142 | Trial comparisons |
| Immunoembolization vs Plain Embolization: serious adverse events | 3 of 26 | 5 of 27 | 53 | NCT00661622 | Trial comparisons |
Arm A (Trametinib) vs Arm B (Trametinib, Akt Inhibitor GSK2141795): Number of Participants With Toxicity, Graded According to the National Cancer Institute CTCAE v4.0, Who Were Treated and Did Not Withdraw Consent | 21 of 21 | 21 of 21 | 42 | NCT01979523 | Trial comparisons |
| Cohort A vs Cohort B: deaths from any cause | 23 of 23 | 14 of 14 | 37 | NCT03207347 | Trial comparisons |
| Cohort A vs Cohort B: serious adverse events | 8 of 23 | 7 of 14 | 37 | NCT03207347 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials43
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006486
GET https://conductscience.org/api/diseases/v1/MONDO_0006486/drugs?page=2